Last reviewed · How we verify
Fluticasone plus salmeterol
Fluticasone plus salmeterol is a Small molecule drug developed by JHSPH Center for Clinical Trials. It is currently FDA-approved.
Fluticasone plus salmeterol is a marketed combination therapy developed by the JHSPH Center for Clinical Trials, currently holding a position in the respiratory disease market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Fluticasone plus salmeterol |
|---|---|
| Sponsor | JHSPH Center for Clinical Trials |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation (NA)
- A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (PHASE3)
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (PHASE4)
- Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation (PHASE3)
- Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion (NA)
- Asthma Research in Children and Adolescents
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone plus salmeterol CI brief — competitive landscape report
- Fluticasone plus salmeterol updates RSS · CI watch RSS
- JHSPH Center for Clinical Trials portfolio CI
Frequently asked questions about Fluticasone plus salmeterol
What is Fluticasone plus salmeterol?
Who makes Fluticasone plus salmeterol?
What development phase is Fluticasone plus salmeterol in?
Related
- Manufacturer: JHSPH Center for Clinical Trials — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing